Movers and SHAKERS
Baudax Bio (BXRX)
Chairman Announces Resignation
Baudax Bio is a biopharmaceutical company focused on developing therapies for post-operative pain, peri-operative pain, and anesthesia. The company currently has one approved therapy in ANJESO for post-operative pain. Proprietary ANJESO (meloxicam) injection is the first and only once-daily IV analgesic. The company also has a pipeline of early-stage candidates with two novel neuromuscular blocking agents (NMBAs), a proprietary related reversal agent to their NMBAs, and Dex-IN, an intranasal formulation of dexmedetomidine (Dex) that has sedative, analgesic, and anti-anxiety properties.
Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Resignation announced. Chairman of the Board of Directors Alfred Altomari announced March 30, 2022, that he was intending to resign. Mr. Altomari has been a director at Baudax Bio since 2019, and was a prior member of the Recro Pharma Board (Recro spun out Baudax Bio to shareholders in 2019). Mr. Altomari has extensive pharmaceutical experience and is currently Chairman and CEO at Agile Therapeutics, and serves on the board of Insmed, Inc.
Resignation effective with shareholder meeting. Mr. Altomari announced that his resignation would be immediately following the Annual Meeting of Shareholders to be held May 4, 2022 ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.